|
January 03, 2022 |
Dear Reader,
A new, easy-to-store COVID-19 vaccine authorized last week by India's drug regulation agency holds the potential to significantly advance global vaccine equity, write Peter J. Hotez and Maria Elena Bottazzi, both at Baylor College of Medicine and the Texas Children's Hospital Center for Vaccine Development. The recombinant protein vaccine, called CORBEVAX, soon will overtake COVID-19 vaccine doses contributed by the U.S. or any other G7 country, the authors write. Read more below about this privately funded development. |
|
|
Vaccines A COVID Vaccine for All With proved technology and no-frills tech transfer, CORBEVAX is poised to reach hundreds of millions in the coming weeks By Peter J. Hotez,Maria Elena Bottazzi | |
Medicine Genetic Therapies for Brain Diseases Hopes are high for a class of drug that could treat neurodegenerative conditions—but a recent clinical trial has brought the field up short | By Diana Kwon,Nature magazine | | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FROM THE STORE | | |
|
|
FROM THE ARCHIVE | | |
LATEST ISSUES |
|
Questions? Comments? | |
Download the Scientific American App |
|
|
Commentaires
Enregistrer un commentaire
Thank you to leave a comment on my site